Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: Implications for treatment

AIDS

Volumn 16, Issue 3, 2002, Pages 493-495

  Pérez Olmeda, Mayte ^a   Ríos, Pilar ^a   Núñez, Marina ^a   García Samaniego, Javier ^a   Romero, Miriam ^a   Soriano, Vincent ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DRUG COMPETITION; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUPERINFECTION; TOXICITY; VIRUS GENOME; VIRUS LOAD; VIRUS TYPING;

ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; RIBAVIRIN; RNA, VIRAL; VIREMIA;

EID: 0037083810     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200202150-00026     Document Type: Article

References (30)

1. Hepatitis C: Prevalence in HIV-infected patients across sectional analysis of the US ACTG
2. Hepatitis C virus infection
3. The influence of hepatitis C on the prognosis of HIV: The EuroSIDA Study
4. Mortality for liver disease in patients with HIV infection: A cohort study
5. Increasing mortality due to end-stage liver disease in patients with HIV infection
6. Hepatitis C virus infection-related morbidity and mortality among patients with HIV infection
7. Impact of chronic viral hepatitis on hospital admission and mortality in HIV-infected patients
8. Interferon alfa for the treatment of chronic hepatitis C in patients with HIV
9. Randomised trial of IFN-alfa 2b plus ribavirin for 48 weeks or 24 weeks versus IFN-alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
10. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
11. Peginterferon alfa-2a in patients with chronic hepatitis C
12. Peginterferon alfa-2b in combination with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: Results of a randomized trial
13. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients
14. Is an 'à la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first-line treatment in patients with chronic hepatitis C?
15. Relationship between HCV genotypes and sources of infection in patients with chronic hepatitis C
16. Hepatitis C virus genotypes in France: Relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP
17. EASL Consensus Statement on hepatitis C
18. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection
19. Impact of immunosuppression caused by HIV infection on the replication of hepatitis C virus
20. High hepatitis C viremia and impaired antibody response in patients coinfected with HIV
21. Hepatitis C viremia in HIV-HCV coinfected patients having immune restoration with HAART
22. Liver damage and kinetics of hepatitis C virus and HIV replication during the early phases of combination antiretroviral treatment
23. Impact of antiretroviral treatment with HIV protease inhibitors on hepatitis C viremia in patients coinfected with HIV
24. Increase in hepatitis C virus load in hemophiliacs during treatment with HAART
25. Second-generation line probe assay for hepatitis C genotyping
26. Performance of the COBAS AMPLICOR HIV MONITOR test, version 2.0, an automated RTPCR quantitative system for hepatitis C virus load determination
27. Hepatitis C virus genotypes: Distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe
28. The prevalence of HCV infection in the United States, 1988 through 1994
29. Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain
30. HCV genotype 4 and response to combination therapy with interferon plus ribavirin